{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T07:40:44Z","timestamp":1778398844960,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T00:00:00Z","timestamp":1326240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00277-011-1394-x","type":"journal-article","created":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T00:57:40Z","timestamp":1326157060000},"page":"923-929","source":"Crossref","is-referenced-by-count":21,"title":["Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting"],"prefix":"10.1007","volume":"91","author":[{"given":"Edgar","family":"Faber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Friedeck\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate\u0159ina","family":"Mi\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0160\u00e1rka","family":"Ro\u017emanov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Divok\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Jaro\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Indr\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,11]]},"reference":[{"key":"1394_CR1","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041\u20136051","journal-title":"J Clin Oncol"},{"key":"1394_CR2","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, O\u2019Brien SG, Riviere GJ, Krahnke T, for the IRIS (International Randomized Interferon vs. STI571) Study Group et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022\u20134028","journal-title":"Blood"},{"key":"1394_CR3","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard M-A et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukemia. Blood 109:3496\u20133499","journal-title":"Blood"},{"key":"1394_CR4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00228-009-0621-z","volume":"65","author":"N Singh","year":"2009","unstructured":"Singh N, Kumar L, Meena R, Velpandian T (2009) Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol 65:545\u2013549","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl. 1","key":"1394_CR5","first-page":"219","volume":"93","author":"E Faber","year":"2008","unstructured":"Faber E, Friedecky D, Tomkova J, Rozmanova S, Rohon P, Skoumalova I et al (2008) Imatinib plasma levels correlate with molecular response in CML patients. Haematologica 93(suppl 1):219\u2013220, Abstract 0543","journal-title":"Haematologica"},{"key":"1394_CR6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","volume":"33","author":"DL Forrest","year":"2009","unstructured":"Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ et al (2009) Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leukemia Res 33:271\u2013275","journal-title":"Leukemia Res"},{"issue":"Suppl. 2","key":"1394_CR7","first-page":"259","volume":"94","author":"A Davies","year":"2009","unstructured":"Davies A, Hayes AK, Giannoudis A, Lucas CM, Knight K, Watmough SJ et al (2009) A study of plasma levels of imatinib and its bioactive metabolite CGP-74588 reveals no correlation with subsequent clinical outcome in imatinib-treated chronic myeloid leukemia. Haematologica 94(suppl 2):259, Abstract 0637","journal-title":"Haematologica"},{"key":"1394_CR8","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","volume":"23","author":"JE Cortes","year":"2009","unstructured":"Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon F-X (2009) Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 23:1537\u20131544","journal-title":"Leukemia"},{"key":"1394_CR9","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simmonsson B, Appelbaum F et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809\u20131820","journal-title":"Blood"},{"key":"1394_CR10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63:789\u2013799","journal-title":"Blood"},{"key":"1394_CR11","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1080\/10428190600565057","volume":"47","author":"E Faber","year":"2006","unstructured":"Faber E, Nau\u0161ov\u00e1 J, Jaro\u0161ov\u00e1 M, Egorin MJ, Holzerov\u00e1 M, Ro\u017emanov\u00e1 \u0160 et al (2006) Intermittent dosage of imatinib mesylate in CML patients with history of significant hematologic toxicity after standard dosing. Leuk Lymphoma 47:1082\u20131090","journal-title":"Leuk Lymphoma"},{"key":"1394_CR12","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","volume":"330","author":"The Italian Cooperative Study Group on Chronic Myeloid Leukemia","year":"1994","unstructured":"The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820\u2013825","journal-title":"N Engl J Med"},{"key":"1394_CR13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","volume":"162","author":"P Chomczynski","year":"1987","unstructured":"Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156\u2013159","journal-title":"Anal Biochem"},{"key":"1394_CR14","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N et al (2003) Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe against cancer program. Leukemia 17:2318\u20132357","journal-title":"Leukemia"},{"key":"1394_CR15","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.cca.2010.08.014","volume":"411","author":"K Mi\u010dov\u00e1","year":"2010","unstructured":"Mi\u010dov\u00e1 K, Friedeck\u00fd D, Faber E, Pol\u00fdnkov\u00e1 A, Adam T (2010) Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma. Clin Chim Acta 411:1957\u20131962","journal-title":"Clin Chim Acta"},{"key":"1394_CR16","doi-asserted-by":"crossref","unstructured":"Osborn MP, White DL, Saunders VA, Cambareri B, Branford S, Menelaou A, et al (2009) Early dose-escalation in chronic myeloid leukaemia patients with low plasma imatinib levels leads to equivalent BCR-ABL values and drug levels at 6\u00a0months to those with optimal drug levels: first analysis from the TIDEL II trial of de-novo patients treated with 600\u00a0mg imatinib. Blood 114(22);Abstract 1131","DOI":"10.1182\/blood.V114.22.1131.1131"},{"key":"1394_CR17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s12185-010-0576-y","volume":"91","author":"E Faber","year":"2010","unstructured":"Faber E, Friedeck\u00fd D, Mi\u010dov\u00e1 K, Divok\u00e1 M, Katrincs\u00e1kov\u00e1 B, Ro\u017emanov\u00e1 \u0160 et al (2010) Imatinib dose escalation in two patients with chronic myeloid leukemia with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response lead to the achievement of higher plasma levels and major molecular response. Int J Hematol 91:897\u2013902","journal-title":"Int J Hematol"},{"key":"1394_CR18","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1349-7006.2010.01643.x","volume":"101","author":"Y Ishikawa","year":"2010","unstructured":"Ishikawa Y, Kiyoi H, Watanabe K, Miyamura K, Nakano Y, Kitamura K et al (2010) Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci 101:2186\u20132192","journal-title":"Cancer Sci"},{"key":"1394_CR19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12185-009-0263-z","volume":"89","author":"M Sakai","year":"2009","unstructured":"Sakai M, Miyazaki Y, Matsuo E, Moriuchi Y, Hata T, Fukushima T et al (2009) Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group. Int J Hematol 89:319\u2013325","journal-title":"Int J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1394-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-011-1394-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1394-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T13:58:34Z","timestamp":1593525514000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-011-1394-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["1394"],"URL":"https:\/\/doi.org\/10.1007\/s00277-011-1394-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,11]]}}}